We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effects of Pioglitazone or Voglibose on Circulating Total and High-Molecular-Weight Adiponectin, and on Two Fibrinolysis Inhibitors, in Patients with Type 2 Diabetes.
- Authors
Aso, Yoshimasa; Yamamoto, Ruriko; Suetsugu, Mariko; Matsumoto, Sachiko; Wakabayashi, Sadao; Matsutomo, Rika; Takebayashi, Kohzo; Inukai, Toshihiko
- Abstract
Obejective. To investigate short-term effects of pioglitazone or voglibose on serum concentrations of both total and high-molecular-weight (HMW) adiponectin measured with a novel sandwich enzyme-linked immunosorbent assay (ELISA) and on plasma fibrinolysis indicators, in type 2 diabetic patients with a second failure of treatment with sulfonylureas. Methods. Thirty-four diabetic patients were randomized to receive pioglitazone or voglibose treatment for 12 weeks, after which serum HMW adiponectin was measured. Plasma plasminogen activator inhibitor (PAI)-1 and thrombin-activatable fibrinolysis inhibitor (TAFI), a recently identified inhibitor of fibrinolysis, were measured as fibrinolysis inhibitors. Results. At baseline, serum HMW adiponectin correlated negatively with plasma TAFI in all patients with type 2 diabetes (r=0.367, P=0.0423). Both groups showed similar improvements in glycemic control. Serum total and HMW adiponectin increased in patients treated with pioglitazone, while showing no significant changes in patients treated with voglibose. The HMW/total adiponectin ratio increased significantly after treatment with pioglitazone (P=0.0004). Changes in HbA1c showed significant negative correlations with changes in serum HMW adiponectin in patients treated with pioglitazone (r=-0.694, P=0.0034). Plasma PAI-1 tended to decrease after pioglitazone treatment (P=0.0908), while plasma TAFI did not change. Conclusion. Increased serum HMW adiponectin may contribute to the improvement in glycemic control after pioglitazone treatment. Plasma PAI-1 decreased somewhat after treatment with pioglitazone, while plasma TAFI was unchanged by either drug.
- Subjects
HYPOGLYCEMIC agents; PROTEIN hormones; ANTIFIBRINOLYTIC agents; PEOPLE with diabetes; TYPE 2 diabetes
- Publication
Diabetes, 2007, Vol 56, pA87
- ISSN
0012-1797
- Publication type
Article